Ondine Biomedical Inc
OBI
Company Profile
Business description
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
Contact
1100 Melville Street
Suite 888
VancouverBCV6E4A6
CANT: +1 604 669-0555
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
8,000
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
Ongoing rate hikes have investors spooked.
stocks
ASX dividend champions: Stocks, ETFs and LICs
Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks
SpaceX’s IPO filing: Big spending, big losses
The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,862.50 | 12.20 | 0.14% |
| CAC 40 | 8,117.42 | 135.66 | 1.70% |
| DAX 40 | 24,737.24 | 336.59 | 1.38% |
| Dow JONES (US) | 50,009.35 | 645.47 | 1.31% |
| FTSE 100 | 10,432.34 | 101.79 | 0.99% |
| HKSE | 25,764.99 | 113.87 | 0.44% |
| NASDAQ | 26,270.36 | 399.65 | 1.54% |
| Nikkei 225 | 61,810.64 | 2,006.23 | 3.35% |
| NZX 50 Index | 12,833.15 | 72.12 | 0.57% |
| S&P 500 | 7,432.97 | 79.36 | 1.08% |
| S&P/ASX 200 | 8,641.20 | 13.20 | 0.15% |
| SSE Composite Index | 4,186.03 | 23.85 | 0.57% |